Quantification of [C]--hydroxyephedrine uptake in human myocardium by unknown
Harms et al. EJNMMI Research 2014, 4:52
http://www.ejnmmires.com/content/4/1/52ORIGINAL RESEARCH Open AccessQuantification of [11C]-meta-hydroxyephedrine
uptake in human myocardium
Hendrik J Harms1*, Stefan de Haan2, Paul Knaapen2, Cornelis P Allaart2, Mischa T Rijnierse2, Robert C Schuit1,
Albert D Windhorst1, Adriaan A Lammertsma1, Marc C Huisman1 and Mark Lubberink3Abstract
Background: The aims of this study were to determine the optimal tracer kinetic model for [11C]-meta-hydroxyephedrine
([11C]HED) and to evaluate the performance of several simplified methods.
Methods: Thirty patients underwent dynamic 60-min [11C]HED scans with online arterial blood sampling. Single-tissue and
both reversible and irreversible two-tissue models were fitted to the data using the metabolite-corrected arterial input
function. For each model, reliable fits were defined as those yielding outcome parameters with a coefficient of
variation (CoV) <25%. The optimal model was determined using Akaike and Schwarz criteria and the F-test, together
with the number of reliable fits. Simulations were performed to study accuracy and precision of each model. Finally,
quantitative results obtained using a population-averaged metabolite correction were evaluated, and simplified retention
index (RI) and standardized uptake value (SUV) results were compared with quantitative volume of distribution (VT) data.
Results: The reversible two-tissue model was preferred in 75.8% of all segments, based on the Akaike information criterion.
However, VT derived using the single-tissue model correlated highly with that of the two-tissue model (r
2 = 0.94, intraclass
correlation coefficient (ICC) = 0.96) and showed higher precision (CoV of 24.6% and 89.2% for single- and two-tissue models,
respectively, at 20% noise). In addition, the single-tissue model yielded reliable fits in 94.6% of all segments as compared
with 77.1% for the reversible two-tissue model. A population-averaged metabolite correction could not be used in
approximately 20% of the patients because of large biases in VT. RI and SUV can provide misleading results
because of non-linear relationships with VT.
Conclusions: Although the reversible two-tissue model provided the best fits, the single-tissue model was
more robust and results obtained were similar. Therefore, the single-tissue model was preferred. RI showed a
non-linear correlation with VT, and therefore, care has to be taken when using RI as a quantitative measure.
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Recently, non-invasive imaging of sympathetic innervation
of the myocardium using PET [1-5] or SPECT [6-8] has
gained interest based on its ability to predict life-threatening
ventricular arrhythmias [9-11] and to assess whether im-
plantable cardioverter defibrillator (ICD) therapy is appro-
priate [12,13]. It has been shown that sympathetic nerve
terminals in the myocardium are more sensitive to ischemic
damage than cardiomyocytes [9,14-21]. In addition, the area
of innervation defects often exceeds the area of non-viable* Correspondence: h.harms@vumc.nl
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in any medium, provided the original work is pscar tissue [9,11,16,17]. More importantly, it has been shown
that areas of viable myocardium, but with impaired innerv-
ation, are related to inducible ventricular tachycardias
originating from these areas [22]. Therefore, non-invasive
imaging of sympathetic innervation may play a key role in
risk stratification and treatment planning in ischemic
cardiomyopathy.
Sympathetic innervation can be measured using the
PET tracers [18 F]-6-fluorodopamine [2], [11C] epineph-
rine [1,3] or [11C]-meta-hydroxyephedrine ([11C]HED)
[4,5], with [11C]HED being used most often. Analysis of
[11C]HED and [11C] epinephrine data often has been
performed using the retention index (RI) [5], a semi-
quantitative parameter that can be derived relativelyn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ity concentrations to the integral of the blood time-
activity curve. However, RI can be sensitive to cardiac
motion, partial volume effects and contribution of intra-
vascular activity and spill-over and therefore may yield
inaccurate results. More quantitative results can be ob-
tained by using compartment models, in which correc-
tion factors for blood volume and spill-over of activity
from the blood can be applied. Interestingly, RI has never
been validated using a direct comparison with quantitative
results obtained from a full tracer kinetic analysis. Further-
more, blood time-activity curves both with [3,22] and
without [23-25] corrections for radioactive metabolites of
[11C]HED have been used for RI, making it difficult to
compare studies. On the other hand, another semi-
quantitative measure, standardized uptake value (SUV),
could provide a further simplification relative to RI, as
it does not require measurement of blood time-activity
curves, nor dynamic scanning.
Only few studies [26,27] have performed quantitative
analysis of [11C]HED data using a single-tissue compart-
ment model, but no systematic assessment of the best
tracer kinetic model was performed. Therefore, the aims
of this study were to determine the optimal tracer kin-
etic model for analysing [11C]HED data and to assess the




Thirty patients (mean age 67 years, range 43 to 80; 26
males) with ischemic cardiomyopathy and a left ven-
tricular ejection fraction below 35%, as determined by
cardiac magnetic resonance imaging (MRI), were in-
cluded. Ischemic cardiomyopathy was defined as having
one or more stenoses >50% on coronary angiography
and delayed contrast enhancement on cardiac MRI. The
study was approved by the Medical Ethics Review Com-
mittee of the VU University Medical Center, and all par-
ticipants gave written informed consent prior to inclusion.
Synthesis of [11C]HED
Radiolabelled [11C]HED was synthesized according to a
GMP-compliant procedure (licence nr. 108879 F), using
a modification of the method of Van Dort and Tluczek
[28]. The starting material, metaraminol (3.0 μmol, 0.5 mg,
purchased from ABX, Radeberg, Germany), was dissolved
in 100 μL of acetonitrile. [11C] Methyl triflate was added to
this solution at room temperature, and after reacting for
1 min, this mixture was diluted with 1 mL of 0.1 M ammo-
nium formate in water. The resulting mixture was injected
onto a Luna C18 5 μm 250*10 mm high-performance li-
quid chromatography (HPLC) column (Phenomenex,
Torrance, CA, USA), which was eluted with a 95/50.1 M ammonium formate/acetonitrile mixture. The
product, [11C]HED, was eluted at 10 min. This fraction
was collected in 60 mL of water for injection. The total
solution was passed over a preconditioned (using 5 mL
of sterile ethanol (96%) and subsequently 10 mL of
water for injection) Oasis WCX cartridge (Waters, Milford,
MA, USA). The cartridge was washed with 20 mL of water
for injection, and subsequently, the product was eluted
from the cartridge with 1.0 mL of sterile ethanol (96%) and
10.0 mL of a sterile and pyrogen-free citrate buffer
(3.8 mM citric acid, 5.4 mM sodium citrate, 5.1 mM
sodium acetate; pH 5.2). This final mixture was passed
over a Millex-GV 0.22 μm filter (Millipore, Billerica,
MA, USA), yielding a sterile, isotonic and pyrogen-free
solution of 1.6 to 5.1 GBq of [11C]HED. The product was
analysed using a GraceSmart RP18 5 μm 250*4.6 mm
HPLC column (Grace, Columbia, MD, USA), which was
eluted with 95/5 0.1 M NaH2PO4 in a water/acetonitrile
mixture. The radiochemical purity was >99% and the
specific activity was 54 to 239 GBq · μmol−1 at the end
of synthesis (N = 30).
Scanning protocol
Studies were performed on a GEMINI TF-64 PET/CT
scanner (Philips Healthcare, Best, the Netherlands) [29].
A 60-min emission scan was started simultaneously with
the injection of 370 MBq [11C]HED, administered as a
5-mL bolus (0.8 mL · s−1) followed by a 35-mL saline flush
(2 mL · s−1). This emission scan was followed immediately
by a respiration-averaged low-dose CT (LD-CT) scan
(55 mAs, rotation time 1.5 s, pitch 0.825, collimation
16 × 0.625, acquiring 20 cm in 37 s compared to 5 s for
a regular LD-CT) during normal breathing.
Images were reconstructed into 36 frames (1 × 10, 8 × 5,
4 × 10, 3 × 20, 5 × 30, 5 × 60, 4 × 150, 4 × 300, 2 × 600 s)
using the 3D row action maximum likelihood algorithm
and applying all appropriate corrections for scanner
normalization, dead time, decay, scatter, randoms and
attenuation based on the corresponding LD-CT scan.
Blood sampling
All patients received an indwelling radial artery catheter
for arterial blood sampling during the dynamic emission
scan. Using an online detection system [30], arterial
blood was withdrawn continuously at a rate of 5 mL ·
min−1 during the first 5 min and 1.7 mL · min−1 there-
after. In addition, 7-mL arterial samples were collected
manually at 2.5, 5, 10, 15, 20, 30, 40 and 60 min post in-
jection and analysed for plasma and whole blood activity
and the presence of radiolabelled metabolites, similarly
as described in [31]. For each sample, activity concentra-
tions in plasma and whole blood were determined. Further-
more, plasma was analysed for radiolabelled metabolites of
[11C]HED by solid-phase extraction (SPE). In brief, 1 mL of
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tivated Oasis WCX cartridge (Waters, Milford, MA, USA,
3 mL, 60 mg). First, the cartridge was washed with 3 mL of
1% acetonitrile in water and subsequently eluted with 3 mL
of 1 M HCl/ethanol (95/5). Radioactivity in all three frac-
tions (plasma, 1% acetonitrile in water, 1 M HCl/ethanol)
was measured. The first two fractions represent polar radi-
olabelled metabolites of [11C]HED and the third intact
[11C]HED. No other metabolites were observed in the third
fraction, and therefore, further analysis using HPLC was
not required.
Input functions
Blood sampler data were corrected for delay and disper-
sion by fitting the early part of the sampler curve to the
ascending aorta (AA) time-activity curve (TAC) using a
single-tissue compartment model with additional param-
eters for delay and dispersion constants [32]. The AA
was chosen as it was shown to provide more reproducible
curves than either the left ventricle or the left atrium [33].
This region was obtained by drawing 1-cm-diameter cir-
cular regions of interest (ROIs) over the AA in at least five
consecutive transaxial images of an early frame of the dy-
namic scan, i.e. the frame in which the first pass of the
bolus through the AA was best visible [34]. To avoid par-
tial volume effects, ROIs were placed in the centre of the
AA, with ROI borders at least 5 mm from the edge of the
AA. Next, the resulting delay- and dispersion-corrected
sampler curve was calibrated using the manually drawn
blood samples. Plasma/whole blood ratios derived from
the manual blood samples were fitted to a sigmoid func-
tion, as described previously [35]. Similarly, parent frac-
tions derived from the same samples were also fitted to a
sigmoid function. Finally, the plasma blood sampler input
function (BSIF) CP(t) was obtained by multiplying the
delay- and dispersion-corrected and calibrated blood TAC
with both these sigmoid functions.
In addition to these individual corrections, a population-
averaged correction for both plasma/whole blood ratios
and parent fractions was obtained using data from ten ran-
domly selected patients, which was applied to all delay-
and dispersion-corrected and calibrated blood TAC.
To correct for spill-over from the right ventricle (RV),
a set of ROIs was placed over the RV cavity in five con-
secutive transaxial planes, with ROI boundaries at least
1 cm away from the RV wall to avoid spill-over of myo-
cardial activity. These ROIs were combined in an RV VOI,
which was then transferred to the full dynamic image se-
quence to obtain the right ventricular time-activity curve.
Data analysis
Using software developed in-house within MATLAB 7.0.4
(MathWorks, Natick, MA, USA), 16 myocardial segment
VOIs were drawn on the final frame of the dynamic scanaccording to the 17-segment model of the American
Heart Association, excluding the apex [36]. This VOI tem-
plate was projected onto the entire dynamic emission scan
to extract segment TACs. Segment TACs were fitted to a
single-tissue compartment model (1T2k) and both an irre-
versible (2T3k) and reversible (2T4k) two-tissue compart-
ment model using non-linear least squares regression. No
additional compartments for metabolites within the heart
were used, as presence of metabolites in the heart was
found to be negligible in a previous preclinical study [4].
Corrections for spill-over from left and right ventricular
cavities were included in all models as follows, based on
the findings in the Appendix:
CPET tð Þ ¼ CT tð Þ þ VA⋅CA tð Þ þ V RV⋅CRV tð Þ ð1Þ
in which CPET(t) represents the measured concentra-
tion, CT(t) the myocardial tissue concentration, CA(t) the
arterial whole blood concentration and CRV(t) the right
ventricular cavity concentration. In Equation 1, RV activ-
ity is treated as spill-over and the VA contribution is as-
sumed to be due to spill-over from the left ventricular
cavity, rather than due to arterial activity within the
myocardium. Clearly, it is not possible to distinguish be-
tween contributions from true myocardial blood volume
and spill-over from the left ventricle, but previously, it
has been shown that assuming VA to be due to spill-over
rather than to myocardial arterial blood volume pro-
vided more stable results for [15O] water [37], which was
confirmed by simulation studies for [11C]HED (Appendix).
Differences in variances of measured activity in each
frame were accounted for by including the following





in which L is the length of each frame, C the total
number of counts of each frame and f the decay correc-
tion factor of each frame. Weights were normalized such
that the average of all weighing factors was equal to
unity.
Outcome parameters for each model are listed in
Table 1 and were defined as in [38]. With the exception
of VS, all parameters were used as independent variables
during the fitting process.
To exclude outliers and unreliable fits, standard devia-
tions of outcome parameters were estimated. Only out-
come parameters with a coefficient of variation (CoV;
standard deviation divided by the final outcome param-
eter) <25% were used for further analysis. For each
model, the number of fits with stable parameters was
used as an outcome measure.
For each segment, the best fit was determined using
the Akaike information criterion (AIC [39]), the Schwarz
Table 1 Outcome parameters for various models
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F-statistic were defined according to Equations 3, 4
and 5, respectively:
AIC ¼ N⋅ ln WSSEð Þ þ 2⋅p ð3Þ








in which N is the number of frames (36 in the present
study), WSSE the weighted squared sum of errors, using
the weights of Equation 2, and p the total number of pa-
rameters for each model, i.e. 4, 5 and 6 for 1T2k, 2T3k
and 2T4k, respectively, including spill-over fractions. The
subscripts 1 and 2 in Equation 5 represent the model with
the highest (2) and the lowest (1) number of parameters.
For the F-test, an F-statistic with a p value <0.05 was con-
sidered to correspond to a significant improvement in the
goodness of fit.
Correlations between volumes of distribution (VT) of
various models and between individual and population-
averaged metabolite corrections were assessed using
linear regressions. Agreement between different VT and
metabolite corrections were assessed using intraclass correl-
ation coefficients (ICC). For validation of the population-
averaged metabolite correction, patients who were used to
define this population average were not included in the
comparison between individual and population corrections.
Finally, RI and SUV were calculated using the last 10 min
of the tissue TAC normalized to the integral of the parent
plasma TAC (RIP) or of the uncorrected whole blood TAC
(RIWB) and to the injected dose divided by patient weight
(SUV), respectively.
Simulations
Simulations were performed using input functions of a
randomly selected patient. Tissue TACs (CPET(t)) were cal-
culated using the reversible two-tissue model for healthy,
scar and viable but denervated tissues. Based on clinical
data obtained after a pilot analysis of five patients, values
for K1, k2, k3 and k4 were set at 0.6 mL · cm
−3 · min−1,
0.15 min−1, 0.3 min−1 and 0.02 min−1 for healthy tis-
sue, at 0.2 mL · cm−3 · min−1, 0.1 min−1, 0.15 min−1 and
0.05 min−1 for scar tissue, and at 0.6 mL · cm−3 · min−1,0.15 min−1, 0.15 min−1 and 0.05 min−1 for viable but
denervated tissue, respectively. An arterial spill-over
fraction of 0.3 and a right ventricular spill-over frac-
tion of 0.1 (dimensionless) were assumed in all settings.
Different levels of Gaussian noise (1%, 5%, 10% and 20%,
representing noise on the whole LV level, the coronary
level, the segmental level and the voxel level, respectively)
were added to tissue TACs, after which they were fitted
using non-linear least squares to each of the three com-
partment models. To correct for differences in variance of
activity in each frame, noise was weighted according to
Equation 2 and the average noise of the final six frames
was set to the aforementioned values of noise levels. For
each noise level, this process was repeated 1,000 times.
Finally, average values of the various outcome parame-
ters together with their CoV were obtained. Bias in de-
rived parameters was obtained by comparing all obtained




For one patient, online sampling could not be performed
due to technical problems, and this patient was excluded
from the study. Typical examples of myocardial TACs
with high and low uptake, together with corresponding
fits, are shown in Figure 1. Based on AIC, the 2T4k,
2T3k and 1T2k models were preferred in 364 (75.8%),
79 (16.4%) and 37 (7.7%) segments, respectively. Based
on SC, this was 324 (67.5%), 99 (20.6%) and 57 (11.9%),
respectively. Finally, the F-test showed a significantly im-
proved fit when using the 2T4k model instead of both
2T3k and 1T2k models in 88.5% and 100% of all seg-
ments, respectively, indicating that the 2T4k model is
the most appropriate model. Both 1T2k and 2T3k
show systematic errors in the obtained fits (runs test
p value <0.001 for both). No systematic error in 2T4k
fits was observed (p = 0.06).
In 76.9%, 96.9% and 99.6% of all segments, K1 was fitted
with a CoV <25% for 2T4k, 2T3k and 1T2k models, re-
spectively. For 2T4k-derived VT (VT,2t), VS and BPND,
2T3k-derived Ki and 1T2k-derived VT (VT,1t), a CoV <25%
was obtained in 77.1%, 77.1%, 23.3%, 86.0% and 94.6% of
all segments, respectively. Due to the very low number of
Figure 1 Typical time-activity curves of heart segments with (A) high and (B) low uptake in the same patient. Red, blue and green lines
represent best fits according to reversible single-tissue (1T2k), irreversible two-tissue (2T3k) and reversible two-tissue (2T4k) models, respectively.
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cluded from further analysis.
Simulations
Simulations showed that, based on both AIC and SC,
preference for the simpler single-tissue model increased
with increasing noise levels (Table 2). Tables 3 and 4
provide accuracy and precision of VT,1t, Ki, VT,2t and K1
estimates for increasing noise levels. In general, accuracy
and precision of VT,2t and K1 derived using 2T4k de-
creased rapidly with increasing noise levels. At increas-
ing noise levels, the best accuracy and precision were
obtained for VT,1t followed by Ki, especially for scar and
viable but denervated tissue. The 1T2k model also pro-
vided the highest precision of K1, especially for tissues
with low uptake, and the lowest noise-induced bias.
Single-tissue vs two-tissue compartment model
The correlation between VT,1t and VT,2t is shown in
Figure 2 for clinical data. Both correlation (r2 = 0.94,
slope = 0.84) and agreement (ICC = 0.96) between VT,1t
and VT,2t were high. VT,1t was significantly lower than
VT,2t, as indicated by the slope, which was significantly
different from 1 (p < 0.001). These results indicate that
VT obtained with the 1T2k model yields the same in-
formation as that obtained with the 2T4k model, albeit
with a consistent underestimation. Consequently, basedTable 2 Model preference (%) at various noise levels accordin
AIC SC
Noise (%) 1T2k 2T3k 2T4k 1T2k 2T3k 2T
1 0.00 0.00 100.00 0.00 0.00 10
5 0.00 5.57 94.43 0.03 8.73 91
10 4.73 27.70 67.57 11.30 33.77 54
20 22.60 47.00 30.40 35.17 47.87 16
Numbers represent the percentage of simulations for which the specific model yiel
which the specific model yielded a significantly (p < 0.05) better fit than the simpleron its better precision, VT,1t was used to validate
simplifications.
Simplifications
Figure 3 shows mean parent [11C]HED fractions and
plasma/whole blood ratios as a function of time. The
corresponding standard deviations indicate substantial
variation between patients. Figure 4 shows a scatter plot
of VT,1t calculated with individual and population-averaged
metabolite corrections. Correlation (r2 = 0.89) and agree-
ment (ICC = 0.94) were high and the slope of the linear fit
was 0.98. However, there was significant bias in several pa-
tients when the population-averaged metabolite correction
was used, ranging from −28% to 34% for individual
patients.
Figure 5 shows relationships of RIP, RIWB and SUV
with VT,1t. There was a clear and strong correlation of
RIP and RIWB with VT,1t (r
2 = 0.77 for RIP and r
2 = 0.76
for RIwb). Correlation of SUV with VT,1t was significantly
lower (r2 = 0.62). It is clear, however, that all three rela-
tionships were non-linear.
Discussion
In the present study, the optimal tracer kinetic model
for kinetic analysis of [11C]HED scans was identified and
several commonly used simplifications were evaluated.
First, Akaike and Schwarz criteria clearly indicated that,g to AIC, SC and F-test
F-test
4k 2T4k over 2T3k 2T4k over 1T2k 2T3k over 1T2k
0.00 100.0 100.00 100.00
.23 93.07 99.63 93.17
.93 55.47 80.43 79.70
.97 23.40 36.13 46.93
ded the lowest AIC or SC or, for the F-test, the percentage of simulations for
model.
Table 3 Average bias (%) for all parameters derived from simulated tissue TACs of all three simulated tissues
Noise K1 1T2k VT 1T2k K1 2T3k Ki 2T3k K1 2T4k VT 2T4k
Healthy 0% −26.37 −22.01 −19.00 21.51 0.00 0.00
1% −26.54 −21.58 −18.99 21.52 0.01 0.31
5% −26.47 −20.97 −18.43 22.36 0.47 7.41
10% −26.37 −18.03 −15.01 27.49 3.76 14.49
20% −26.17 −10.74 −6.73 39.91 8.23 15.56
Scar 0% −22.07 −11.97 −15.27 41.21 0.00 0.00
1% −22.26 −11.88 −15.26 41.23 0.00 0.20
5% −22.26 −11.78 −15.21 41.32 0.57 14.19
10% −22.32 −10.73 −14.50 42.50 3.12 95.17
20% −21.79 −8.99 −11.65 47.25 14.08 208.98
Denervated 0% −29.56 −12.35 −20.71 58.59 0.00 0.00
1% −29.79 −12.35 −20.68 58.63 0.03 0.02
5% −29.74 −12.19 −20.72 58.56 0.28 1.24
10% −29.68 −12.13 −20.39 59.22 0.38 18.55
20% −29.52 −10.95 −18.95 62.10 4.33 82.07
Bias was calculated by comparing the obtained values of K1, VT and Ki with those used in the 2T4k model to generate time-activity curves (i.e. the 2T4k model has
no bias for 0% noise). Bias due to noise can be appreciated by comparing the obtained bias with those at 0% noise.
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ible two-tissue model was the preferred model for describ-
ing [11C]HED kinetics. Similar results were obtained when
using the F-test, which is insensitive to any potential bias
introduced in AIC and SC due to the scaling factors as
presented in Equations 3 and 4. This confirms that, based
on goodness of fit, the reversible two-tissue model was the
optimal model. Simulations, on the other hand, also indi-
cated that with increasing noise levels (starting at 5%
noise, corresponding with noise at the level of the coron-
ary territory), precision of all parameter estimates using
this model rapidly decreased (Table 3) and that, for higher
noise levels, model preference shifted towards models
with fewer parameters (Table 2). In addition, for clinical
data, the number of reliable estimates was lower for theTable 4 CoV (%) for all parameters derived from simulated ti
Noise K1 1T2k VT 1T2k








Denervated 1% 0.36 0.65
5% 1.74 3.02
10% 3.60 6.32
20% 6.82 13.452T4k parameters VT,2t,VS and BPND (77.1, 77.1 and 23.3%,
respectively) than for Ki derived using the 2T3k model
(86.0%) and VT,1t obtained using the 1T2k model (94.6%).
The large number of estimates with high uncertainty indi-
cates that the use of the reversible two-tissue model may
not be feasible in routine clinical practice, as it would
mean discarding over 20% of all data. In addition, most es-
timates with high uncertainty in 2T4k parameters were in
regions with reduced [11C]HED uptake, indicating that the
2T4k model is especially vulnerable in diseased myocar-
dium, which significantly limits the applicability of this
model.
For the reversible two-tissue model, the total volume
of distribution can be separated in specific and non-
specific volumes of distribution. In this study, the totalssue TACs of all three simulated tissue classes
K1 2T3k Ki 2T3k K1 2T4k VT 2T4k
0.98 1.85 1.39 3.96
5.06 17.22 6.95 21.32
10.71 36.97 11.61 28.82
21.74 48.47 17.21 35.20
0.63 4.28 1.09 1.71
3.17 25.10 5.47 65.24
5.89 48.29 9.77 136.43
10.46 68.38 23.92 133.26
0.52 2.93 0.76 1.08
2.69 15.53 3.91 8.52
4.92 32.84 7.88 68.26
9.75 56.64 16.11 99.17
Figure 2 Correlation of VT,1t (vertical axis) with VT,2t (horizontal
axis) for clinical data.
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of distribution and enabled the use of the simpler single-
tissue model, as the contribution of the non-specific
compartment was very small, if not negligible. As shown
in Figure 2,VT,1t yields similar results to VT,2t, indicating
that the single-tissue model yields similar information to
the reversible two-tissue model. In addition, precision
was much higher for VT,1t than for VT,2t (Tables 3 and 4)
and noise-induced biases were lower for VT,1t. Since the
single-tissue model is simpler, more stable and less sen-
sitive to noise compared with the reversible two-tissue
model, it is preferred for further use, especially for
smaller regions or regions with relatively low uptake.
In this study, arterial activity was assumed to be spill-
over from the arterial blood pool, rather than activity
originating from arterial blood within the tissue. BothFigure 3 Parent fraction in arterial plasma (A) and plasma/whole bloo
mean values and red lines mean values ± one standard deviation.assumptions are physiologically not fully correct and
ideally, a combination should be used. However, differ-
entiating between contributions from spill-over and myo-
cardial blood volume is impossible, as kinetics of both
contributions are identical. Previously, it has been shown
that, in a comparison of MBF as measured with [15O]
water against labelled microspheres, assuming arterial ac-
tivity to be spill-over yields more accurate results [37], at
least for [15O] water. A simulation study (see Figure 6 in
Appendix) showed that the same is true for HED, al-
though a bias was found in both implementations. Bias
was smallest when arterial activity was assumed to be due
to spill-over. In addition, arterial blood volume fraction
within myocardial tissue is relatively constant in the myo-
cardium [41], and therefore, it is expected that bias in the
spill-over implementation, which is dependent on the
magnitude of this blood volume fraction, is more consist-
ent than bias in the tissue blood volume implementation,
which depends on the recovery of the scanner and seg-
ment size.
The use of HED as an innervation tracer has recently
been debated [42], where it was suggested that HED is a
flow-limited rather than innervation-limited tracer. This
was suggested to lead to the impossibility to fit HED
data using standard kinetic modelling techniques and
make HED uptake insensitive to early changes in innerv-
ation. However, when performing tracer kinetic analyses,
parameters representing innervation (i.e. Ki, VT, VS and
BPND) can be obtained together with parameters repre-
senting flow and extraction (i.e. K1). This enables separ-
ating flow effects from innervation effects by studying
both K1 and, when the 1T2k model is used, VT. Further-
more, in this study we show that, utilizing plasma input
functions fully corrected for radiolabelled metabolites
and plasma-to-blood concentration ratios, HED could
reliably be fitted using a 2T4k model or, with slightly
poorer fits, using a 1T2k model, which is in contrast to
the suggestion in [42].d concentration ratio (B) as a function of time. Blue lines indicate
Figure 5 RIP (A), RIWB (B) and SUV (C) as a function of corresponding
concentrations between 50 and 60 min post injection to the total amount
blood (RIWB) and injected dose per patient weight (SUV), respectively.
Figure 4 Correlation plot of VT,1t calculated using individual
metabolite corrections (horizontal axis) and population-averaged
metabolite correction (vertical axis). Each patient (n = 20) is
represented by its own symbol.
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does indicate that for RI it might be the case that early
changes are not readily detected. Indeed, when a sensi-
tivity analysis is performed for changes in k3, which repre-
sents HED uptake through the norepinephrine transporter,
using K1, k2 and k4 of 0.6 mL · cm
−3 · min−1, 0.15 min−1 and
0.02 min−1, respectively, and gradually decreasing k3, RI
showed a lower and non-linear sensitivity to changes in
innervation (see Additional file 1). On the other hand,VT,1t
showed good sensitivity to changes in innervation, where
decreases in VT,1t were similar to decreases in k3, confirm-
ing that VT,1t is a more reliable measure of innervation
than RI. Nevertheless, sensitivity of RI to changes in k3
may still be sufficient for routine clinical use as large re-
ductions in k3 are readily detected by RI. It is also import-
ant to note that another recent study [43] showed that
HED was able to detect early changes in innervation, con-
firming that HED is likely to represent innervation even
when using RI.
Potentially, a population-averaged metabolite correc-
tion could, in combination with an image-derived input
function, make arterial cannulation obsolete. There was,
however, substantial variation in individual metabolism
(Figure 3), resulting in large errors of up to 30% in fitted
parameters when using a population-averaged metaboliteVT,1t. RIP, RIWB and SUV were obtained by normalizing radioactivity
of [11C]HED in plasma (RIP), total amount of radioactivity in whole
Figure 6 Bias due to interpretation of blood activity. Bias in % for estimates of K1 (A) and VT (B) derived using 1T2k (red) and 2T4k (blue)
models using interpretations BV (continuous lines) and SO (dashed lines) for healthy tissue. Please note that the sum of VA and VSO was set to 0.3
for all simulated tissue curves.
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http://www.ejnmmires.com/content/4/1/52correction (Figure 4) for approximately 20% of the patients.
Clearly, for absolute quantification, a population-averaged
metabolite correction is not feasible, at least not in the case
of [11C]HED, as a method that produces inaccurate results
in as much as 20% of the cases should be discarded. How-
ever, when relative differences within a single patient are
of interest, e.g. when assessing defect areas (percentage of
LV with VT below a reference value), population-averaged
metabolite corrections can be considered. Using venous
samples for metabolite correction might be an alternative
for both relative analysis and absolute quantification, but
this requires further validation.
In addition, the use of an image-derived input function
would be preferred over the use of online blood sam-
pling. However, image-derived input functions require
validation for each individual radiotracer and preliminary
results for [11C]HED [44] have shown that late activity
concentrations were overestimated in the image-derived
input functions, which is in line with observations in other
studies that made use of a combination of image-derived
input function and blood sampler data [26,27]. Given the
fact that an image-derived input function can be used for
other tracers such as [15O] water [45] and [18 F] FDG [33],
the particular biodistribution of HED with its high con-
trast between the myocardium and the blood at later time
points, together with high liver uptake, will require im-
proved reconstruction methods and/or scatter correction
algorithms before an image-derived input function can be
used for [11C]HED.
A reasonable correlation was found between VT,1t and
either RIP, RIWB or SUV (r
2 = 0.77, 0.76 and 0.62, re-
spectively). These correlations suggest that RIP, RIWB
and SUV may be used to distinguish innervated from de-
nervated regions of the myocardium. However, it should
be noted that relationships were non-linear (Figure 5).
Consequently, these simplified measures will be less
sensitive in detecting early changes in regions withhigh innervation, e.g. in early disease, or for monitor-
ing response during treatment. In these cases, the use
of quantitative measures is recommended. On the other
hand, for routine clinical (diagnostic) use, RI might be suf-
ficient, as large reductions in HED uptake are reflected in
large reductions in RI. In addition, simplified methods
may lead to biased estimates of defect sizes, as these usu-
ally are derived using cut-off values, which are based
on a percentage of uptake in a reference region within
the heart. Due to the non-linear relationships, cut-off
values for RIP, RIWB and SUV will be different from
those for VT,1t and, consequently, defect areas may dif-
fer significantly.
In the present study, RI was based on uptake between
50 and 60 min post injection, whilst 30 to 40 min is
more commonly used. When RI was calculated using
uptake from 30 to 40 min post injection, similar results
were obtained (r2 = 0.72 and r2 = 0.73 for RIP and RIWB,
respectively). For RIP, this correlation was slightly, but
significantly, lower than that for the 50 to 60 min uptake
period (p = 0.043). For RIWB, this difference was not sta-
tistically significant (p = 0.071). Although correlation with
VT,1t was still reasonable, based on these findings, it is rec-
ommended to use later times for measuring RI due to the
slow kinetics of HED.
Finally, it is important to note that the aforementioned
results and interpretations are made from a modelling
point of view, i.e. which parameter describes the mea-
sured HED activity best. This might be different from
which parameter actually describes myocardial presynap-
tic activity best. Ideally, a blocking study or animal study
should be performed to compare the obtained parame-
ters with a gold standard measurement. In addition, the
performance of the quantitative parameters used in the
present study needs to be assessed in clinical studies, as
the added clinical value of VT over simplified measures
such as RIP still needs to be defined. Whilst simulations
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are more sensitive to changes in k3, the rate constant
reflecting norepinephrine transport, RI also showed sig-
nificant correlation with k3, suggesting that RI may be
sufficiently sensitive for measuring (changes in) innerv-
ation. Further clinical validation studies using RIP, RIWB,
SUV and VT are warranted.
Conclusions
Although a reversible two-tissue compartment model best
describes [11C]HED kinetics, a single-tissue compartment
model is preferred for routine clinical studies, as it is more
robust at clinically relevant noise levels and, at the same
time, provides VT results that are highly correlated with
those obtained with the two-tissue compartment model.
Simplified measures, such as RI and SUV, showed good
correlation with fully quantitative results and may be used
to detect regions of denervation, although the non-linear
relationship with VT might limit their application in, for
instance, monitoring response to treatment.
Appendix
Contribution of arterial activity measured within a myo-
cardial region is typically the combination of two differ-
ent effects: a physical blood volume fraction within the
myocardium and spill-over of activity from the left ven-
tricular cavity into the myocardium. This can be repre-
sented as follows:
CPET tð Þ ¼ 1−VAð Þ⋅CT tð Þ þ VA þ V LVð Þ⋅CA tð Þ
þV RV⋅CRV tð Þ
ðA1Þ
in which CT(t) represents the HED concentrations in
the myocardial tissue itself whilst CPET(t), CA(t) and CRV
(t) represent the measured regional, arterial and right
ventricular blood activity concentrations, respectively.
VA represents the actual arterial blood volume fraction
in the tissue, and VLV and VRV represent the spill-over
fractions from the left and the right ventricular cavity,
respectively. During compartment modelling, it is not
possible to distinguish VA from VLV, and therefore, the
estimated arterial activity measured within a myocardial
region can be interpreted in two different ways:
CPET tð Þ ¼ CT tð Þ þ V LV⋅CA tð Þ þ V RV⋅CRV tð Þ ðA2Þ
CPET tð Þ ¼ 1−VAð Þ⋅CT tð Þ þ VA⋅CA tð Þ þ V RV⋅CRV tð Þ
ðA3Þ
Interpretation SO (spill-over, Equation A2) assumes all
measured arterial activity in the tissue regions to be due
to spill-over from the left ventricular cavity, and a correc-
tion factor VA ·CA(t) is used to correct for this spill-overfraction. In contrast, interpretation BV (blood volume,
Equation A3) assumes all arterial activity in the tissue re-
gions to be due to intravascular activity originating from
the arterial blood volume within the myocardium itself.
Since measured K1 represents K1 in the myocardial tissue
only, a correction factor for tissue fraction has to be ap-
plied in model BV, in addition to the correction factor VA ·
CA(t). This tissue fraction is estimated as 1 −VA. In reality,
measured activity originates from both spill-over from the
left ventricular cavity and myocardial arterial blood, but it
is impossible to distinguish between both contributions
and, in practice, only a single correction can be applied. It
is important to note that the actual fits obtained using
Equations A2 and A3 are identical and only the interpret-
ation of K1 and consequently VT is different.
To define the optimal model implementation, a simu-
lation study was performed for both model interpreta-
tions. Three tissue curves (i.e. healthy tissue, scar tissue
and viable but denervated tissue) were defined, using the
same parameters as for the noise simulations. VRV was
0.1 for all simulated tissue curves. For each of the three
tissue curves, arterial activity was simulated to be due to
both spill-over from the left ventricular cavity (VLV) and
arterial blood volume in the myocardium (VA) using
Equation A1.
The total contribution of arterial blood activity was set
to 0.3, based on clinical data (average VA for all seg-
ments 0.30 ± 0.10, 0.28 ± 0.10 and 0.25 ± 0.11 for 1T2k,
2T3k and 2T4k models, respectively), and VRV was set
to 0.1, again based on clinical data (average VRV for all
segments 0.07 ± 0.08, 0.06 ± 0.07 and 0.06 ± 0.07 for 1T2k,
2T3k and 2T4k models, respectively, and for septal seg-
ments alone 0.14 ± 0.09, 0.13 ± 0.09 and 0.13 ± 0.09 for
1T2k, 2T3k and 2T4k models, respectively). For each tis-
sue curve, a simulation was performed with VA set to 0.1,
0.15 and 0.2 and VLV to 0.2, 0.15 and 0.1, respectively. In
addition, for each tissue curve, VA, VLV and VRV were set
to 0 and a fit was performed to obtain estimates without
any confounding effects of VA, VLV and VRV, and these
values were used as reference values. Then, the obtained
time-activity curves were fitted using both Equations A2
and A3 and the reversible one- and two-tissue compart-
ment models, and the obtained K1 and VT were compared
with the reference values. For healthy tissue, bias in the
obtained results is shown in Figure 6. Similar results were
obtained for scar and viable but denervated tissue. As ex-
pected, bias was observed for both BV and SO. In general,
magnitude and variation in bias were larger for BV than
for SO, indicating that estimates obtained with SO are
more stable and closer to the true simulated tissue values.
For these reasons, SO was considered to be the most ro-
bust model interpretation. In addition,VA is relatively con-
stant in the myocardium (around 10% [41]), and therefore,
it is likely that spill-over has a larger and more variable
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http://www.ejnmmires.com/content/4/1/52contribution to VA. Therefore, it is expected that bias in
SO, which is dependent on the magnitude of VA, is also
relatively constant. In contrast, bias in BV is dependent on
the magnitude of VLV, which depends on scanner reso-
lution, segment size and thickness of the myocardial wall,
and therefore, it is expected to vary between patients and
scans. For these reasons, SO was used in the present
study.Additional file
Additional file 1: Figure S1. Results of sensitivity analysis, showing
relative change in k3 (x-axis, representing transport through the
norepinephrine transporter) and resulting relative changes in fitted
outcome measures. Dashed line represents line of identity.
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